Name (Synonyms) | Correlation | |
---|---|---|
drug790 | Covid-19 presto test Wiki | 0.71 |
drug2606 | Serology for Covid-19 Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D018410 | Pneumonia, Bacterial NIH | 0.71 |
D008173 | Lung Diseases, Obstructive NIH | 0.24 |
D008171 | Lung Diseases, NIH | 0.17 |
D011024 | Pneumonia, Viral NIH | 0.09 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.06 |
D011014 | Pneumonia NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006536 | Pulmonary obstruction HPO | 0.24 |
HP:0002088 | Abnormal lung morphology HPO | 0.17 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
Description: The percent of samples from the fully enrolled cohort to return a valid SARS-CoV-2 test result (positive, not detected, or inconclusive)
Measure: Valid SARS-CoV-2 Test Time: Subjects are assessed at enrollmentThe purpose of this research study is 1) to conduct a prospective longitudinal surveillance research trial, enrolling up to 200 CCHMC employees as they come back to work, and then following their clinical and laboratory parameters for up to 12 months; and 2) to support the ongoing development of diagnostic techniques for COVID-19. The overall goal is to investigate patterns of SARS-COV-2 infection, including immunological recovery and genetic risk factors, among CCHMC employees to better understand how to safely reintroduce the CCHMC work force back into their normal routines.
Description: Acquired COVID is defined as testing negative for COVID at baseline and having 1 or more weekly nasal swab samples testing positive for the virus by PCR
Measure: The 6-month cumulative incidence of acquired COVID infection in the study cohort. Time: Weekly for 6 months